Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2018-12-07T16:30:21Z | - |
dc.date.available | 2018-12-07T16:30:21Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1107-0625 | * |
dc.identifier.other | OAK-21494 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247283 | - |
dc.description.abstract | Purpose: To evaluate the outcomes of chemoradiotherapy (CRT) after neoadjuvant chemotherapy consisting of gemcitabine and erlotinib for unresectable locally advanced pancreatic cancer. Methods: Between 2010 and 2014, 24 patients with unresectable pancreatic cancer received neoadjuvant gemcitabine/erlotinib followed by CRT. There were 9 men and 15 women, and median age was 61 years (range 48-77). Radiotherapy (RT) was delivered to the tumor and regional lymph nodes with a median dose of 50.4 Gy (range 50.4-56). All patients received concurrent chemotherapy, with 5-fluorouracil (5-FU), capecitabine or gemcitabine and 17 patients received maintenance chemotherapy with gemcitabine plus erlotinib, 5-FU plus leukovorin or capecitabine plus oxaliplatin. The median follow-up period was 17 months (range 7-31). Results: The median overall survival (OS) and post-RT OS (PROS) were 17.8 and 10.7 months, respectively. On multivariate analysis, RT dose (p=0.005) and maintenance chemotherapy (p=0.019) were significant prognostic factors for OS. In addition, RT dose ?54Gy (p=0.021) and concurrent gemcitabine (p=0.012) were identified as favorable prognostic factors for PROS. Grade 3 hematologic and gastrointestinal toxicities occurred in 3 and 2 patients, respectively. Conclusions: Intensive treatment with gemcitabine-based CRT, high RT dose, and maintenance chemotherapy may improve survival outcomes in locally advanced pancreatic cancer patients receiving neoadjuvant gemcitabine/erlotinib. © 2017 Zerbinis Publications. All rights reserved. | * |
dc.language | English | * |
dc.publisher | Zerbinis Publications | * |
dc.subject | Chemoradiotherapy | * |
dc.subject | Induction chemotherapy | * |
dc.subject | Pancreatic neoplasms | * |
dc.subject | Unresectable | * |
dc.title | Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer | * |
dc.type | Review | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 22 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1046 | * |
dc.relation.lastpage | 1052 | * |
dc.relation.journaltitle | Journal of B.U.ON. | * |
dc.identifier.wosid | WOS:000412789500035 | * |
dc.identifier.scopusid | 2-s2.0-85045584042 | * |
dc.author.google | Kim E. | * |
dc.author.google | Kim K. | * |
dc.author.google | Chie E.K. | * |
dc.author.google | Oh D.-Y. | * |
dc.author.google | Kim Y.T. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240222162403 | * |